Kyowa Hakko Kirin Co., Ltd. announced that it resolved the following changes in its Executive Directors at its Board of Directors meeting held on February 5, 2019. The changes will be formally approved in the 96th Ordinary General Meeting of Shareholders to be held on March 2019 and the Board of Directors meeting after the General Meeting of Shareholders. Kyowa Hakko Kirin's smooth progress in its initiatives aimed at evolving into a global specialty pharmaceutical company, it has been decided that now is an opportune time for Nobuo Hanai, who is presently serving as Executive Director of the Board, Chairman, to relinquish his representative authority. Kyowa Hakko Kirin will work toward further strengthening its corporate governance by entrusting a larger share of business execution to the management led by the President and better clarifying the role of the Chairman as one of supervising business execution. In line with these changes, Kyowa Hakko Kirin wishes to newly appoint Yutaka Osawa, who is presently serving as Director of the Board, Managing Executive Officer, to the position of Director of the Board, Vice President(In charge of Internal Audit Department), and grant him representative authority.